Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2013-05-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-013-2566-2PMID 23695655
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

  2012cited by this paper
• Extensive up-regulation of gene expression in cancer: the normalised use of microarray data.

  2012cited by this paper
• Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

  2012cited by this paper
• Top scoring pairs for feature selection in machine learning and applications to cancer outcome prediction

  2011cited by this paper
• Statistical Applications in Genetics and Molecular Biology Classifying Gene Expression Profiles from Pairwise mRNA Comparisons

  2011cited by this paper
• A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

  2011cited by this paper
• Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer

  2010cited by this paper
• The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models

  2010cited by this paper
• Multi-level reproducibility of signature hubs in human interactome for breast cancer metastasis

  2010cited by this paper
• Tackling the widespread and critical impact of batch effects in high-throughput data

  2010cited by this paper
• Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.

  2010influential reference
• Do predictive signatures really predict response to cancer chemotherapy?

  2010cited by this paper
• Synergistic drug combinations improve therapeutic selectivity

  2009cited by this paper
• Evaluating reproducibility of differential expression discoveries in microarray studies by considering correlated molecular changes

  2009cited by this paper
• Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.

  2009cited by this paper
• Genomic grade index is associated with response to chemotherapy in patients with breast cancer.

  2009cited by this paper
• Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.

  2008cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• Apparently low reproducibility of true differential expression discoveries in microarray studies

  2008cited by this paper
• Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied

  2008cited by this paper
• Prognostic value of initial clinical disease stage after achieving pathological complete response.

  2008cited by this paper
• Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

  2007cited by this paper
• ASPP: a new family of oncogenes and tumour suppressor genes

  2007cited by this paper
• Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.

  2007cited by this paper
• Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.

  2007cited by this paper
• Bias in error estimation when using cross-validation for model selection

  2006cited by this paper
• ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth.

  2006cited by this paper
• Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

  2006cited by this paper
• Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.

  2006cited by this paper
• Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

  2006cited by this paper
• Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

  2006influential reference
• Simple decision rules for classifying human cancers from gene expression profiles

  2005cited by this paper
• Limits of predictive models using microarray data for breast cancer clinical treatment outcome.

  2005cited by this paper
• International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.

  2003cited by this paper
• p53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis

  2001cited by this paper
• Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.

  2001cited by this paper
• ASPP proteins specifically stimulate the apoptotic function of p53.

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper

• The Prostate

  2020cites this paper
• Early Diagnosis of Hepatocellular Carcinoma Using Machine Learning Method

  2020cites this paper
• A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy

  2020cites this paper
• A qualitative transcriptional prognostic signature for patients with stage I-II pancreatic ductal adenocarcinoma.

  2020cites this paper
• A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy

  2020cites this paper
• A Qualitative Transcriptional Signature for Predicting Recurrence Risk of Stage I–III Bladder Cancer Patients After Surgical Resection

  2019cites this paper
• A qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy.

  2019cites this paper
• Identifying disease-associated pathways in one-phenotype data based on reversal gene expression orderings

  2017cites this paper
• An individualized prognostic signature and multi-omics distinction for early stage hepatocellular carcinoma patients with surgical resection

  2016cites this paper
• Autophagy‐related prognostic signature for breast cancer

  2016cites this paper
• Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples

  2016cites this paper
• Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer

  2015cites this paper
• Overexpression of ILK1 in breast cancer associates with poor prognosis

  2013cites this paper